|
1
|
Collaborative Group: Combination
chemotherapy versus melphalan plus prednisone as treatment for
multiple myeloma: An overview of 6,633 patients from 27 randomized
trials. Myeloma Trialists' Collaborative Group. J Clin Oncol.
16:3832–3842. 1998.PubMed/NCBI
|
|
2
|
Harousseau JL and Attal M: The role of
autologous hematopoietic stem cell transplantation in multiple
myeloma. Semin Hematol. 34(1 Suppl 1): 61–66. 1997.PubMed/NCBI
|
|
3
|
Blade J, Rosinol L, Cibera MT, Rovira M
and Carreras E: Hematopoietic stem cell transplantation for
multiple myeloma beyond 2010. Blood. 115:3655–3663. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van de Velde HJ, Liu X, Chen G, Cakana A,
Deraedt W and Bayssas M: Complete response correlates with
long-term survival and progression-free survival in high-dose
therapy in multiple myeloma. Haematologica. 92:1399–1406. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar S, Flinn I, Richardson PG, Hari P,
Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, et
al: Randomized, multicenter, phase 2 study (EVOLUTION) of
combinations of bortezomib, dexamethasone, cyclophosphamide and
lenalidomide in previously untreated multiple myeloma. Blood.
119:4375–4382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chanan-Kahn AA and Giralt S: Importance of
achieving complete response in multiple myeloma and the impact of
novel agents. J Clin Oncol. 28:2612–2624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boccadoro M, Cavallo F, Nagler A, Ben
Yehuda D, Omedè P, Cavalli M, Levi A, Crippa C, Siniscalchi A,
Brasca P, et al: Melphalan/prednisone/lenalidomide (MPR) versus
high-dose melphalan and autologous transplantation (MEL200) in
newly diagnosed multiple myeloma (MM) patients: a phase III trial.
J Clin Oncol. 29(Supp 1): 8020–8027. 2011.
|
|
8
|
Gay F, Hajek R, Diramondo F, et al:
Cyclophosphamide lenalidomide-dexamethasone vs. autologous
transplant in newly diagnosed myeloma: a phase 3 trial. Clin
Lymphoma Myeloma Leuk. 13(Suppl 1): S402013.
|
|
9
|
Fermand JP, Katsahian S, Divine M, et al:
High-dose therapy and autologous blood stem-cell transplantation
compared with conventional treatment in myeloma patients aged 55 to
65 years: long-term results of a randomized control trial from the
Group Myelome-Autogreffe. J Clin Oncol. 23:9227–9233. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hahn T, Wingard JR, Anderson KC, et al:
The role of cytotoxic therapy with hematopoietic stem cell
transplantation in the therapy of multiple myeloma: an
evidence-based review. Biol Blood Marrow Transplant. 9:4–37. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moreau P, Avet-Loiseau H, Facon T, Attal
M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C,
et al: Bortezomib plus dexamethasone versus reduced-dose
bortezomib, thalidomide plus dexamethasone as induction treatment
before autologous stem cell transplantation in newly diagnosed
multiple myeloma. Blood. 118:5752–5758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jakubowiak AJ, Griffith KA, Reece DE,
Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman
RL, Laubach JP, Raje NS, et al: Lenalidomide, bortezomib, pegylated
liposomal doxorubicin and dexamethasone in newly diagnosed multiple
myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood. 118:535–543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kenneth C Anderson, Melissa Alsina,
William Bensinger, et al: Multiple Myeloma. Version 1.2013 J Natl
Compr Canc Netw. 11:11–17. 2013.
|
|
14
|
Durie BG, Harousseau JL, Miguel JS, et al:
International uniform response criteria for multiple myeloma.
Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haroussear JL, Attal M and Avet-Loiseau H:
The role of complete response in multiple myeloma. Blood.
114:3139–3146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Attal M, Harousseau JL, Stoppa AM, Sotto
JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah
N, et al: A prospective, randomized trial of autologous bone marrow
transplantation and chemotherapy in multiple myeloma. Intergroupe
Français du Myélome. N Engl J Med. 335:91–97. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Child JA, Morgan GJ, Davies FE, Owen RG,
Bell SE, Hawkins K, Brown J, Drayson MT and Selby PJ: Medical
Research Council Adult Leukaemia Working Party: High-dose
chemotherapy with hematopoietic stem-cell rescue for multiple
myeloma. N Engl J Med. 348:1875–1883. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harousseau JL, Palumbo A, Richardson PG,
Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M,
Golenkov A, et al: Superior outcomes associated with complete
response in newly diagnosed multiple myeloma patients treated with
nonintensive therapy: analysis of the phase 3 VISTA study of
bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood. 116:3743–3750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reeder CB, Reece DE, Kukreti V, Chen C,
Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, et al:
Cyclophosphamide, bortezomib and dexamethasone induction for newly
diagnosed multiple myeloma: high response rates in a phase II
clinical trial. Leukemia. 23:1337–1341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar L, Iqbal N, Mookerjee A, Verma RK,
Sharma OD, Batra A, Pramanik R and Gupta R: Complete response after
autologous stem cell transplant in multiple myeloma. Cancer Med.
3:939–946. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spencer A, Prince HM, Roberts AW, Prosser
IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J and
Kennedy N: Consolidation therapy with low-dose thalidomide and
prednisolone prolongs the survival of multiple myeloma patients
undergoing a single autologous stem-cell transplantation procedure.
J Clin Oncol. 27:1788–1793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Attal M, Harousseau JL, Leyvraz S, Doyen
C, Hulin C, Benboubker L, Agha Yakoub I, Bourhis JH, Garderet L,
Pegourie B, et al: Inter-Groupe Francophone du Myélome (IFM).:
Maintenance therapy with thalidomide improves survival in patients
with multiple myeloma. Blood. 108:3289–3294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barlogie B, Tricot G, Anaissie E,
Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M,
Hollmig K, Pineda-Roman M, et al: Thalidomide and hematopoietic
cell transplantation for multiple myeloma. N Engl J Med.
354:1021–1030. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Attal M and Roussel M: Maintenance therapy
for myeloma. How much, how long and at what cost? Am Soc Clin Oncol
Educ Book. 32:515–522. 2012.
|
|
25
|
Kapoor P, Kumar SK, Dispenzieri A, et al:
Importance of achieving stringent complete response after
autologous stem-cell transplantation in multiple myeloma. J Clin
Oncol. 31:4529–4535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bergantim R, Trigo F and Guimaraes JE:
Impact of tandem autologous stem cell transplantation and response
to transplant in the outcome of multiple myeloma. Exp Hematol
Oncol. 1:35–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinez-Lopez J, Blade J, Mateos MV, et
al: Long-term prognostic significance of response in multiple
myeloma after stem cell transplantation. Blood. 118:529–534. 2011.
View Article : Google Scholar : PubMed/NCBI
|
